250 related articles for article (PubMed ID: 28012258)
1. Functional defect of variants in the adenosine triphosphate-binding sites of ABCB4 and their rescue by the cystic fibrosis transmembrane conductance regulator potentiator, ivacaftor (VX-770).
Delaunay JL; Bruneau A; Hoffmann B; Durand-Schneider AM; Barbu V; Jacquemin E; Maurice M; Housset C; Callebaut I; Aït-Slimane T
Hepatology; 2017 Feb; 65(2):560-570. PubMed ID: 28012258
[TBL] [Abstract][Full Text] [Related]
2. Ivacaftor-Mediated Potentiation of ABCB4 Missense Mutations Affecting Critical Motifs of the NBDs: Repositioning Perspectives for Hepatobiliary Diseases.
Delaunay JL; Elbahnsi A; Bruneau A; Madry C; Durand-Schneider AM; Stary A; Housset C; Gautheron J; Callebaut I; Aït-Slimane T
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674751
[TBL] [Abstract][Full Text] [Related]
3. Functional rescue of an ABCB11 mutant by ivacaftor: A new targeted pharmacotherapy approach in bile salt export pump deficiency.
Mareux E; Lapalus M; Amzal R; Almes M; Aït-Slimane T; Delaunay JL; Adnot P; Collado-Hilly M; Davit-Spraul A; Falguières T; Callebaut I; Gonzales E; Jacquemin E
Liver Int; 2020 Aug; 40(8):1917-1925. PubMed ID: 32433800
[TBL] [Abstract][Full Text] [Related]
4. Mutation-specific dual potentiators maximize rescue of CFTR gating mutants.
Veit G; Da Fonte DF; Avramescu RG; Premchandar A; Bagdany M; Xu H; Bensinger D; Stubba D; Schmidt B; Matouk E; Lukacs GL
J Cyst Fibros; 2020 Mar; 19(2):236-244. PubMed ID: 31678009
[TBL] [Abstract][Full Text] [Related]
5. Effect of CFTR correctors on the traffic and the function of intracellularly retained ABCB4 variants.
Ben Saad A; Vauthier V; Tóth Á; Janaszkiewicz A; Durand-Schneider AM; Bruneau A; Delaunay JL; Lapalus M; Mareux E; Garcin I; Gonzales E; Housset C; Aït-Slimane T; Jacquemin E; Di Meo F; Falguières T
Liver Int; 2021 Jun; 41(6):1344-1357. PubMed ID: 33650203
[TBL] [Abstract][Full Text] [Related]
6. Structural mechanisms for defective CFTR gating caused by the Q1412X mutation, a severe Class VI pathogenic mutation in cystic fibrosis.
Yeh JT; Yu YC; Hwang TC
J Physiol; 2019 Jan; 597(2):543-560. PubMed ID: 30408177
[TBL] [Abstract][Full Text] [Related]
7. Cystic fibrosis transmembrane conductance regulator (CFTR) potentiator VX-770 (ivacaftor) opens the defective channel gate of mutant CFTR in a phosphorylation-dependent but ATP-independent manner.
Eckford PD; Li C; Ramjeesingh M; Bear CE
J Biol Chem; 2012 Oct; 287(44):36639-49. PubMed ID: 22942289
[TBL] [Abstract][Full Text] [Related]
8. Potentiator synergy in rectal organoids carrying S1251N, G551D, or F508del CFTR mutations.
Dekkers JF; Van Mourik P; Vonk AM; Kruisselbrink E; Berkers G; de Winter-de Groot KM; Janssens HM; Bronsveld I; van der Ent CK; de Jonge HR; Beekman JM
J Cyst Fibros; 2016 Sep; 15(5):568-78. PubMed ID: 27160424
[TBL] [Abstract][Full Text] [Related]
9. Resveratrol and ivacaftor are additive G551D CFTR-channel potentiators: therapeutic implications for cystic fibrosis sinus disease.
Cho DY; Zhang S; Lazrak A; Grayson JW; Peña Garcia JA; Skinner DF; Lim DJ; Mackey C; Banks C; Matalon S; Woodworth BA
Int Forum Allergy Rhinol; 2019 Jan; 9(1):100-105. PubMed ID: 30152192
[TBL] [Abstract][Full Text] [Related]
10. A small molecule CFTR potentiator restores ATP-dependent channel gating to the cystic fibrosis mutant G551D-CFTR.
Liu J; Berg AP; Wang Y; Jantarajit W; Sutcliffe KJ; Stevens EB; Cao L; Pregel MJ; Sheppard DN
Br J Pharmacol; 2022 Apr; 179(7):1319-1337. PubMed ID: 34644413
[TBL] [Abstract][Full Text] [Related]
11. Synergistic Potentiation of Cystic Fibrosis Transmembrane Conductance Regulator Gating by Two Chemically Distinct Potentiators, Ivacaftor (VX-770) and 5-Nitro-2-(3-Phenylpropylamino) Benzoate.
Lin WY; Sohma Y; Hwang TC
Mol Pharmacol; 2016 Sep; 90(3):275-85. PubMed ID: 27413118
[TBL] [Abstract][Full Text] [Related]
12. Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function.
Van Goor F; Yu H; Burton B; Hoffman BJ
J Cyst Fibros; 2014 Jan; 13(1):29-36. PubMed ID: 23891399
[TBL] [Abstract][Full Text] [Related]
13. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.
Pettit RS
Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718
[TBL] [Abstract][Full Text] [Related]
14. On the mechanism of gating defects caused by the R117H mutation in cystic fibrosis transmembrane conductance regulator.
Yu YC; Sohma Y; Hwang TC
J Physiol; 2016 Jun; 594(12):3227-44. PubMed ID: 26846474
[TBL] [Abstract][Full Text] [Related]
15. Lipophilicity of the Cystic Fibrosis Drug, Ivacaftor (VX-770), and Its Destabilizing Effect on the Major CF-causing Mutation: F508del.
Chin S; Hung M; Won A; Wu YS; Ahmadi S; Yang D; Elmallah S; Toutah K; Hamilton CM; Young RN; Viirre RD; Yip CM; Bear CE
Mol Pharmacol; 2018 Aug; 94(2):917-925. PubMed ID: 29903751
[TBL] [Abstract][Full Text] [Related]
16. Vx-770 potentiates CFTR function by promoting decoupling between the gating cycle and ATP hydrolysis cycle.
Jih KY; Hwang TC
Proc Natl Acad Sci U S A; 2013 Mar; 110(11):4404-9. PubMed ID: 23440202
[TBL] [Abstract][Full Text] [Related]
17. CFTR-dependent chloride efflux in cystic fibrosis mononuclear cells is increased by ivacaftor therapy.
Guerra L; D'Oria S; Favia M; Castellani S; Santostasi T; Polizzi AM; Mariggiò MA; Gallo C; Casavola V; Montemurro P; Leonetti G; Manca A; Conese M
Pediatr Pulmonol; 2017 Jul; 52(7):900-908. PubMed ID: 28445004
[TBL] [Abstract][Full Text] [Related]
18. The Cystic Fibrosis Transmembrane Conductance Regulator Potentiator Ivacaftor Augments Mucociliary Clearance Abrogating Cystic Fibrosis Transmembrane Conductance Regulator Inhibition by Cigarette Smoke.
Raju SV; Lin VY; Liu L; McNicholas CM; Karki S; Sloane PA; Tang L; Jackson PL; Wang W; Wilson L; Macon KJ; Mazur M; Kappes JC; DeLucas LJ; Barnes S; Kirk K; Tearney GJ; Rowe SM
Am J Respir Cell Mol Biol; 2017 Jan; 56(1):99-108. PubMed ID: 27585394
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic benefit observed with the CFTR potentiator, ivacaftor, in a CF patient homozygous for the W1282X CFTR nonsense mutation.
Mutyam V; Libby EF; Peng N; Hadjiliadis D; Bonk M; Solomon GM; Rowe SM
J Cyst Fibros; 2017 Jan; 16(1):24-29. PubMed ID: 27707539
[TBL] [Abstract][Full Text] [Related]
20. A common mechanism for CFTR potentiators.
Yeh HI; Sohma Y; Conrath K; Hwang TC
J Gen Physiol; 2017 Dec; 149(12):1105-1118. PubMed ID: 29079713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
